호흡기 진단 시장 : 제품 유형, 적응증, 최종 사용자별 - 세계 예측(2025-2030년)

The Respiratory Diagnostics Market was valued at USD 6.12 billion in 2023, expected to reach USD 6.66 billion in 2024, and is projected to grow at a CAGR of 8.67%, to USD 10.96 billion by 2030.

The respiratory diagnostics market encompasses a wide range of tests, devices, and technologies aimed at identifying respiratory conditions such as asthma, COPD, and other lung-related illnesses. This market is pivotal due to the rising global prevalence of respiratory diseases, fueled by factors such as pollution, smoking, and aging populations. The necessity of accurate, efficient diagnostic tools is paramount to improve patient outcomes, manage chronic diseases, and reduce healthcare costs. These diagnostics are utilized in numerous applications, including hospitals, clinics, laboratories, and home care settings, with end-use scopes varying from disease prediction to therapy management.

Key growth drivers include advancements in diagnostic technologies, such as molecular diagnostics and AI integration, which enhance accuracy and speed. Increasing healthcare expenditure, alongside greater awareness about respiratory health, further propels the market. A potential opportunity lies in the burgeoning demand for point-of-care testing devices, driven by the need for rapid and precise diagnosis in epidemic-prone regions. However, challenges like high costs of advanced diagnostics, lack of skilled professionals, and regulatory hurdles may impede market growth. Competitive pricing pressure in a highly fragmented market also presents a significant barrier.

For business growth, innovation areas include wearable respiratory monitors, telemedicine-integrated diagnostics, and development of personalized medicine approaches. Companies should also leverage AI and big data analytics for enhanced predictive analytics and decision-making processes. Collaborations between diagnostic manufacturers and digital health platforms could provide a competitive edge by expanding product reach and improving consumer engagement. Despite the promising outlook, staying abreast of evolving regulations and investing in training programs to address skill gaps are essential. The market's nature being highly dynamic and competitive necessitates companies to continuously innovate and adapt to changing consumer preferences and technological advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Diagnostics Market

The Respiratory Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing aging population with susceptibility to chronic respiratory diseases
  • Growth in the approvals for respiratory disease diagnostic kits, tests, and systems
  • Rising preferences for remote and home care testing devices
• Market Restraints
  • Incidences of product recall of respiratory diagnosis panels and kits with limited reimbursement policies
• Market Opportunities
  • Technological advancements to introduce sophisticated respiratory diagnostic tools
  • Government initiatives and funding for respiratory diagnostic tools
• Market Challenges
  • Risk of errors associated with complex diagnostic procedures

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Diagnostics Market

A detailed market share analysis in the Respiratory Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Adaltis S.r.l., Masimo Corporation, Merck KGaA, Somnoware by ResMed Corp., ProAxsis by NetScientific PLC, Medtronic PLC, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, Becton, Dickinson, and Company, Seegene Inc., Siemens Healthineers AG, Abbott Laboratories, Vitalograph Ltd., Bioneer Corporation, Altona Diagnostics GmbH, CerTest Biotec S.L., GE HealthCare Technologies, Inc., Dragerwerk AG & Co. KGaA, Quidel Corporation, Daan Gene Co., Ltd., bioMerieux S.A., SDI Diagnostics, Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., Sansure Biotech Inc., Johnson & Johnson Services, Inc., Thermo Fisher Scientific Inc., ZeptoMetrix LLC, and Diatech Pharmacogenetics srl.

Market Segmentation & Coverage

This research report categorizes the Respiratory Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Assays & Reagents, Instruments & Devices, and Software & Services.
• Based on Test Type, market is studied across Imaging Tests, Mechanical Tests, Molecular Diagnostic Tests, OSA Diagnostic Tests, and Traditional Diagnostic Tests. The Imaging Tests is further studied across Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, and X-Ray. The Mechanical Tests is further studied across Peak Flow Test, Pulmonary Function Tests, and Spirometry. The Molecular Diagnostic Tests is further studied across DNA Sequencing & Next-Generation Sequencing, In Situ Hybridization, Microarrays, Nucleic Acid Amplification Test, and PCR. The Traditional Diagnostic Tests is further studied across Biochemical Tests, Immunodiagnostics, and Microscopy.
• Based on Indication, market is studied across Asthma, Chronic Obstructive Pulmonary Disease, Lung Cancer, Pneumonia, and Tuberculosis.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing aging population with susceptibility to chronic respiratory diseases
    • 5.1.1.2. Growth in the approvals for respiratory disease diagnostic kits, tests, and systems
    • 5.1.1.3. Rising preferences for remote and home care testing devices
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of product recall of respiratory diagnosis panels and kits with limited reimbursement policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements to introduce sophisticated respiratory diagnostic tools
    • 5.1.3.2. Government initiatives and funding for respiratory diagnostic tools
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of errors associated with complex diagnostic procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Need for rapid detection of pathogens driving the adoption of assays and reagents
  • 5.2.2. Test Type: Research initiatives to advance the accuracy and specificity of molecular diagnostic tests
  • 5.2.3. Indication: Need for advanced respiratory diagnostic technologies to attain accurate testing of chronic obstructive pulmonary disease
  • 5.2.4. End-User: Adoption of a diverse range of diagnostic tools in hospitals and clinics for identifying and monitoring respiratory ailments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Respiratory Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Assays & Reagents
• 6.3. Instruments & Devices
• 6.4. Software & Services

7. Respiratory Diagnostics Market, by Test Type

• 7.1. Introduction
• 7.2. Imaging Tests
  • 7.2.1. Computed Tomography
  • 7.2.2. Magnetic Resonance Imaging
  • 7.2.3. Positron Emission Tomography
  • 7.2.4. X-Ray
• 7.3. Mechanical Tests
  • 7.3.1. Peak Flow Test
  • 7.3.2. Pulmonary Function Tests
  • 7.3.3. Spirometry
• 7.4. Molecular Diagnostic Tests
  • 7.4.1. DNA Sequencing & Next-Generation Sequencing
  • 7.4.2. In Situ Hybridization
  • 7.4.3. Microarrays
  • 7.4.4. Nucleic Acid Amplification Test
  • 7.4.5. PCR
• 7.5. OSA Diagnostic Tests
• 7.6. Traditional Diagnostic Tests
  • 7.6.1. Biochemical Tests
  • 7.6.2. Immunodiagnostics
  • 7.6.3. Microscopy

8. Respiratory Diagnostics Market, by Indication

• 8.1. Introduction
• 8.2. Asthma
• 8.3. Chronic Obstructive Pulmonary Disease
• 8.4. Lung Cancer
• 8.5. Pneumonia
• 8.6. Tuberculosis

9. Respiratory Diagnostics Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals & Clinics
• 9.4. Research Institutes

10. Americas Respiratory Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Respiratory Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Respiratory Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. NYU Langone Health Enters 8-Year Partnership with Philips
  • 13.3.2. Masimo Gets De Novo Approval From FDA for ORi
  • 13.3.3. bioMerieux Submits Dual 510(k) and CLIA-Waiver Application to FDA for the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel
  • 13.3.4. BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test
  • 13.3.5. ResMed Acquires Sleep and Respiratory Diagnostics Software Maker Somnoware
  • 13.3.6. Seegene Obtains IVDR Certification for 30 Diagnostic Assays
  • 13.3.7. Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
  • 13.3.8. QIAGEN Launches QIAstat-Dx in Japan with Respiratory Panel for Syndromic Testing
  • 13.3.9. Thermo Fisher partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
  • 13.3.10. Molbio Diagnostics adds Truenat H3N2/H1N1 Test to Respiratory Disease Portfolio
  • 13.3.11. Vitalograph Launches New Respiratory VitaloPFT Series
  • 13.3.12. SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
  • 13.3.13. Philips and Masimo Expand Partnership To Improve Telehealth For Patients And Clinicians Around The World

Companies Mentioned

• 1. Adaltis S.r.l.
• 2. Masimo Corporation
• 3. Merck KGaA
• 4. Somnoware by ResMed Corp.
• 5. ProAxsis by NetScientific PLC
• 6. Medtronic PLC
• 7. Hologic, Inc.
• 8. F. Hoffmann-La Roche Ltd.
• 9. Quest Diagnostics Incorporated
• 10. Becton, Dickinson, and Company
• 11. Seegene Inc.
• 12. Siemens Healthineers AG
• 13. Abbott Laboratories
• 14. Vitalograph Ltd.
• 15. Bioneer Corporation
• 16. Altona Diagnostics GmbH
• 17. CerTest Biotec S.L.
• 18. GE HealthCare Technologies, Inc.
• 19. Dragerwerk AG & Co. KGaA
• 20. Quidel Corporation
• 21. Daan Gene Co., Ltd.
• 22. bioMerieux S.A.
• 23. SDI Diagnostics, Inc.
• 24. Koninklijke Philips N.V.
• 25. Bio-Rad Laboratories, Inc.
• 26. Sansure Biotech Inc.
• 27. Johnson & Johnson Services, Inc.
• 28. Thermo Fisher Scientific Inc.
• 29. ZeptoMetrix LLC
• 30. Diatech Pharmacogenetics srl